HeartSciences (HSCSW) Cash from Financing Activities (2022 - 2026)

HeartSciences has reported Cash from Financing Activities for 5 years, with the latest figure at $2.9 million in Q1 2026.

• For the quarter ending Q1 2026, Cash from Financing Activities rose 1529.6% year-over-year to $2.9 million; the trailing twelve-month figure through Jan 2026 stood at $8.2 million (up 172.14% YoY), and the FY2025 full-year result was $2.7 million, down 73.57% from the prior year.
• Cash from Financing Activities for Q1 2026 stood at $2.9 million, up from $1.5 million in the prior quarter.
• The five-year high for Cash from Financing Activities was $9.1 million in Q1 2024, with the low at -$121522.0 in Q1 2023.
• Historically, Cash from Financing Activities has averaged $1.8 million across 5 years, with a median of $782374.0 in 2022.
• Annual changes were most pronounced in 2023 — Cash from Financing Activities tumbled 106.32% — and 2024, when it jumped 7610.17%.
• HeartSciences' Cash from Financing Activities stood at -$116392.0 in 2022, then surged by 542.15% to $514629.0 in 2023, then surged by 269.53% to $1.9 million in 2024, then fell by 20.66% to $1.5 million in 2025, then surged by 94.6% to $2.9 million in 2026.
• The last three Cash from Financing Activities figures came in at $2.9 million (Q1 2026), $1.5 million (Q4 2025), and $3.6 million (Q3 2025), per Business Quant data.